BAGSVAERD, Denmark—Novo Holdings, the Danish drugmaker’s controlling shareholder, said it acquired New Jersey-based Catalent Inc. in a deal that values the contract manufacturer at $16.5 billion. Novo Nordisk, in turn, said it will acquire three manufacturing sites from Novo Holdings for $11 billion.